More patients to become eligible for chronic kidney disease treatment
The UK National Institute for Health and Care Excellence (NICE) has published updated Final Draft Guidance recommending AstraZeneca’s Forxiga (dapagliflozin) as an option to treat chronic kidney disease (CKD) in adults in certain cases.
This is the case if:
- It is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors and angiotensin-2 receptor antagonists, unless these are contraindicated, and
- People have an estimated glomerular filtration rate (eGFR) of:
- 20 ml/min/1.73 m2 to less than 45 ml/min/1.73 m2, or
- 45 ml/min/1.73 m2 to 90 ml/min/1.73 m2, and either:
- A urine albumin-to-creatine ratio (uACR) of 22.6 mg/mmol or more, or
- Type 2 diabetes.
This evaluation was a review of NICE’s technology appraisal guidance on dapagliflozin for treating CKD, published in 20221,2. It also reviewed new data submitted by AstraZeneca as part of this evaluation1.
This decision means dapagliflozin is now recommended as a treatment option for CKD in a wider patient population – expanding patient access outside of the eGFR restrictions outlined in NICE’s final appraisal document in 20221,2.
NICE’s decision comes soon after the acceptance from the Scottish Medicines Consortium (SMC) for the same indication and expanded patient population in April 2025.
CKD prevenance
CKD is a long-term condition, categorised by the gradual loss of kidney function – hindering the removal of waste products from the body3,4. An estimated 7.2 million people in the UK currently live with CKD, which equates to more than 10% of the entire population2. Of these, around one million are unaware they have this condition5.
With cases in the UK growing so rapidly, if projected figures for the number of dialysis patients are realised, it risks costing the UK economy approximately £14 billion annually by 20336. CKD also represents a significant burden on the UK healthcare system, accounting for over 100,000 unplanned hospital admissions in England and Wales every year7.
Fiona Loud, Policy Director at Kidney Care UK, said: “This is a significant development for people with early-stage kidney disease. Slowing down kidney disease can be life-changing, particularly if it reduces the chances of someone needing dialysis or a kidney transplant. The availability of this treatment provides even more incentive for monitoring people most at risk of chronic kidney disease, as it enables diagnosis and appropriate treatment as early as possible.”
Tom Keith-Roach, President, AstraZeneca UK, said: “We are delighted by NICE’s decision to broaden access to dapagliflozin for patients with CKD. This milestone reflects AstraZeneca’s ongoing commitment to advancing innovative treatments that can make a difference to patient’s lives. CKD places significant burden on patients, their families and our healthcare services and we are proud to play a part in addressing this growing health challenge. We look forward to working in partnership with the health system to ensure eligible patients can benefit from this important therapy as soon as possible.”
CKD is progressive and is often considered a silent disease in its early stages as many patients don’t show symptoms until the disease is already at an advanced stage8. People living with CKD have markedly elevated risk of cardiovascular (CV) events, with CV disease being the leading cause of death for this patient population9,10.
The recommendation from NICE is based on the submission of several data sets, including analysis of RWE (OPTIMISE-CKD), and data from previous clinical studies of dapagliflozin (DAPA-CKD, DAPA-HF and DECLARE-TIMI 58)1. These data sets provided significant evidence for the benefit of dapagliflozin in patients outside of the eligibility restrictions in eGFR, as outlined in the final appraisal document from NICE in 20221,5.
Megan Thomas, Multimedia Editor, DDW
References
- National Institute for Health and Care Excellence. Final Draft Guidance. Dapagliflozin for treating chronic kidney disease. Issue date: 30 May 2025.
- National Institute for Health and Care Excellence. Final Draft Guidance. Dapagliflozin for treating chronic kidney disease. Issue date: 3 February 2022.
- Elendu C, et al. Comprehensive review of current management guidelines of chronic kidney disease. Medicine. 2023;102(23):e33984.
- Overview – Dialysis. Available at: https://www.nhs.uk/conditions/dialysis/. Last accessed: May 2025.
- Kidney Care UK. One in four people not aware of the main signs of chronic kidney disease. Available at: https://kidneycareuk.org/news-from-kidney-care-uk/one-in-four-people-unaware-of-the-main-signs-of-chronic-kidney-disease/#:~:text=CKD%20currently%20affects%20one%20in%20ten%20people%20%E2%80%93,those%20are%20not%20even%20aware%20they%20have%20CKD. Last accessed: May 2025.
- Kidney Research UK. Kidney disease: A UK public health emergency. Available at: https://www.kidneyresearchuk.org/wp-content/uploads/2023/06/Economics-of-Kidney-Disease-full-report_accessible.pdf. Last accessed: May 2025.
- Healthcare Quality Improvement Partnership. National Chronic Kidney Disease Audit 2017: National Report (Part 2). Available at: https://www.hqip.org.uk/wp-content/uploads/2018/02/national-chronic-kidney-disease-audit-national-report-part-2.pdf. Last accessed: May 2025.
- Symptoms – Chronic Kidney Disease. Available at: https://www.nhs.uk/conditions/kidney-disease/symptoms/. Last accessed: May 2025.
- Zaccali C, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovascular Research. 2023;119(11):2017-2031.
- Jun M, et al. Managing Cardiovascular Risk in People with Chronic Kidney Disease: A Review of the Evidence from Randomized Controlled Trials. Ther Adv Chronic Dis. 2011;2(4):265-278.
